Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children (U01)

The summary for the Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children (U01): The NIDDK invites Cooperative Agreement applications for a limited competition from the two Clinical Coordinating Centers (CCC), the Data Coordinating Center (DCC) and the Central Biochemistry Laboratory (CBL) already involved in The Chronic Kidney Disease in Children (CKiD) consortium. The Clinical Centers will continue to evaluate enrolled subjects, recruit new subjects, and continue to work together cooperatively with the existing DCC and CBL of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).

Federal Grant Title:	Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Food and Nutrition Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-12-507
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.837
CFDA Descriptions:	Cardiovascular Diseases Research
Current Application Deadline:	Nov 14, 2012
Original Application Deadline:	Nov 14, 2012
Posted Date:	August 31st, 2012
Creation Date:	Aug 31, 2012
Archive Date:	Dec 15, 2012
Total Program Funding:	$3,200,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24 Clinical Trial Not...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial No...; • The Relationship Between Hypertension and Inflammation; • Community-Responsive Interventions to Reduce Cardiovascular Risk in American Indians and A...; • Weight Loss in Obese Adults with Cardiovascular Risk Factors: Clinical Interventions (U01)
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...